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Objectives: Adherence and health-related quality of life (HRQoL) are two impor-
tant indicators in determining success of drug treatments. Although medication 
adherence and HRQoL have been studied intensively, less is known about the asso-
ciation of these factors. This research aims to undertake a systematic review of the 
published literature on the relationship of medication adherence and HRQoL in 
patients with chronic obstructive pulmonary disease (COPD). No comprehensive 
review has been published in this topic so far. MethOds: Peer-reviewed English-
language articles that examined the relationship between adherence/compliance/
persistence to medication and HRQoL in COPD were identified through database 
(Medline, EMBASE) searches. Reports until April 2013 were screened. Papers related 
to oxygen therapy were excluded. Results: Of the 243 papers reviewed, eight stud-
ies met the inclusion criteria and were analyzed in our systematic review. Evidence 
suggests that relationship between medication adherence and HRQoL is dual. Non-
adherence does not have a clear negative impact on HRQoL. Adherence to medica-
tion may affect HRQoL due to more factors, such as effectiveness/efficacy and side 
effects of the medication, daily life limitation and social stigmatization caused by 
the therapy. Effect of non-adherence on HRQoL can be derived from the resultant 
of these factors. Nevertheless, HRQoL may also influence patients’ drug use; poor 
or good HRQoL may trigger non-adherence. Relationship between adherence and 
HRQoL may differ depend on the duration of the previous therapy (as therapy in 
newly diagnosed COPD patients may improve HRQoL more than in patients treated 
previously for longer durations) and on the study design (cross-sectional versus 
longitudinal follow-up study) as well. cOnclusiOns: Association of medication 
adherence and HRQoL is multiple. Results from previous studies are limited. Further 
scientific evaluations are needed to better understand the dynamics between these 
factors. Such information would be critically important and needs to be considered 
when integrating adherence into health-economic evaluations.
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Objectives: Chronic obstructive pulmonary disease (COPD) is a major public health 
problem and one of the leading causes of chronic morbidity and mortality worldwide. 
This study aims at determining generic utilities for Spanish COPD patients stratified by 
international guidelines GOLD 2006 (airflow limitation) and GOLD 2013 (airflow limita-
tion, exacerbation history and symptoms), and Spanish guidelines GesEPOC (clinical 
phenotypes). MethOds: Multicentre, observational, cross-sectional study, carried out 
in 15 Pulmonology Spanish public services, including patients aged 40+, diagnosed with 
COPD, who have not experienced an exacerbation in the previous 2 months and receiv-
ing pharmacological treatment for COPD. Utilities were derived from EQ-5D-3L scores. 
Medians, means and standard deviations (SD) were computed for groups of patients 
based on GOLD 2006, GOLD 2013 and GesEPOC classifications. Differences in median 
utilities between groups were assessed by means of Kruskal-Wallis tests. Post-hoc pair-
wise comparisons were based on Wilcoxon tests (Bonferroni-adjusted). Results: A 
total of 346 patients were included in the analysis. Statistically significant median dif-
ferences in utilities by groups of patients were found. GOLD 2006: moderate (n= 135, 
median= 0.87, mean= 0.81, SD= 0.22); severe (n= 145, median= 0.80, mean= 0.71, SD= 0.29); 
very severe (n= 66, median= 0.67, mean= 0.57, SD= 0.35); (p< 0.001). All pair-wise compari-
sons were statistically significant (p< 0.001). GOLD 2013: group A (n= 28, median= 0.98, 
mean= 0.94, SD= 0.06); group B (n= 66, median= 0.87, mean= 0.80, SD= 0.22); group C (n= 30, 
median= 0.98, mean= 0.87, SD= 0.24); group D (n= 222, median= 0.74, mean= 0.66, SD= 0.30); 
(p< 0.001). All pair-wise comparisons were statistically significant (p< 0.002), except-
ing groups A and C comparison. GesEPOC: (A) non-exacerbator (n= 215, median= 0.84, 
mean= 0.78, SD= 0.23); (B) overlap COPD-asthma (n= 21, median= 0.80, mean= 0.80, 
SD= 0.19); (C) exacerbator with emphysema (n= 46, median= 0.74, mean= 0.59, SD= 0.40); 
(D) exacerbator with chronic bronchitis (n= 64, median= 0.74, mean= 0.62, SD= 0.33); 
(p< 0.001). Pair-wise comparisons between phenotypes A and C (p< 0.002) and pheno-
types A and D (p< 0.001) were statistically significant. cOnclusiOns: Generic utilities 
are associated with airflow limitation, exacerbation history, symptoms and clinical 
phenotypes in a sample of Spanish COPD patients.
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Objectives: 1) To identify COPD products approved with a Patient-Reported Outcome 
(PRO) labeling claim in Europe and the USA, and 2) to list the differences found in 
Europe vs. the USA in terms of products and labeling. MethOds: The search was 
performed on the FDA- and EMA-approved medicinal product labels and medical 
reviews/scientific discussions (from January 1995 - February 2013 inclusive). Results: 
A total of 25 COPD products were retrieved: 11 were approved by the EMA and 14 
by the FDA. Only three INN were approved by both agencies (aclidinium bromide, 
indacaterol, and roflumilast), representing 11 products (EMA, n= 8; FDA, n= 3). Out of 
the 25 products approved, 15 have a PRO claim (EMA, n= 8; FDA, n= 7). When focusing 
on the INN approved by both agencies, the review showed that the FDA and the EMA 
agreed on the granting of a PRO claim (i.e., “yes” for aclidinium bromide and inda-
caterol, and “no” for roflumilast). The FDA and the EMA reviewed the same clinical 
studies. However, the labeling text differs between the agencies. The FDA label of acli-
dinium bromide does not provide any mention of results measured by the St. George’s 
Respiratory Questionnaire (SGRQ) and the Transition Dyspnoea Index (TDI), while the 
EMA label does. As for indacaterol, the FDA label does not mention any TDI results, 
while the EMA label does. Reasons for these discrepancies are found in the FDA medi-
cal reviews. The TDI has been assessed as inadequate for use as a CT endpoint. As for 
the SGRQ, the results met the threshold of clinically meaningful improvement in only 
Both groups were similar at baseline. Drop out was 28.8%. Intention to treat analysis. 
Adherence increased significantly in IG (p= 0.046), NNT= 6.37 (CI95%,3.25-142.8). Factors 
related to adherence: intervention (OR= 1.88, CI95%,1.01-3.52), number of exacerbation 
(OR= 0.66,CI95%,0.48-0.91), number of visits to health centre (OR= 0.93,CI95%,0.87-1.00), 
severity (OR= 0.677,CI95%,0.43-1.04), number of devices (OR= 2.4,CI95%,1.09-5.30), SGRQ-
Activity scale (OR= 0.978,CI95%,0.95-1.00), SGRQ-Impact scale (OR= 1.03,CI95%,1.00-1.06), 
inhaled-beta2-adrenérgic (OR= 0.16, CI95%,0.059-0.43), xanthine (OR= 0.199, CI95%,0.05-
0.77). Rho coefficient= 6.07x10-6 (p= 0.498). cOnclusiOns: The more adherent patient 
was that who showed a lower number of visits to health centre, exacerbations, number 
of devices, level of severity, and impact on daily activities but with higher disease impact. 
The beta-2-adrenergic and xanthine treatment are associated with no adherence.
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Objectives: To test the inhaler use in COPD patients. Frequent mistakes. MethOds: 
Design: Cross-sectional study at the beginning of a Multicenter patients’ prefer-
ence trial (ISRCTN15106246) Patients: 465 COPD patients from 9 health care centres, 
with inhaled treatment, written consent. Non-probabilistic consecutive sampling. 
Variables: inhaler devices, performance of correct inhalation technique, type of mis-
takes. Age, sex, Inhalatory pick flow, COPD severity stage, prescribed medication. 
Basal dyspnea index (BDI). Statistical analysis: Mean, frequency. 95% confidence inter-
val. Results: Predominance of males (91.4%), mean age 69.8 years (CI95%,69.00-70.59); 
FEV1(mean)= 55.91%(IC95:53.62-58.2), mixed respiratory pattern (65.9%). Severity stage: 
15.7% mild, 44.1% Moderate, 40.3% Severe. Pharmacological treatment: inhaled-beta2-
adrenergic (88.8%); inhaled-corticosteroids (76.7%); inhaled-anticholinergic (70.7%); 
mucolitycs (19.4%); xanthine (7.3%); oral-corticosteroids (1.3%). BDI: grade 2. Inhalation 
technique: 84.9% had received instruction about inhalation techniques (48.6% from neu-
mologist, 42.1% from general practitioner). The instruction was an explanation without 
device (59.6%). 67.3% of patients used Handihaler, 54.8% Accuhaler, 31.8% Turbuhaler, 
26.9% pressurised metered dose inhaler (pMDI). The 91.3% of patients performed an 
incorrect inhalation technique with handihaler, 89.5% with Turbuhaler, 85.6% with 
Accuhaler and 91.7% with pMDI. The most common mistakes in all devices were related 
to the action consist on: emptying or almost emptying the lungs before activating the 
spray (79.8%) and holding breath for at least 8-10 seconds or for as long as possible 
when inhalation is complete (69.5%). The most common mistakes per device were 
related to: repeating the inhalation with Handihaler (10%), Loading the dispenser cor-
rectly in Accuhaler (8.2%) or Turbuhaler (16.6%) and hand-breath coordination in pMDI 
(52.8%). cOnclusiOns: A high percentage of patients with COPD performed an incor-
rect inhalation technique although they had been received instruction about this. The 
most common mistakes are more related to the patient’s attitude than to the type of 
device.
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Objectives: to test the efficacy of two educational interventions to improve the 
inhalation techniques in patients with COPD and the influence of patient’ prefer-
ence. MethOds: Design: Multicenter patients’ preference trial or comprehensive 
cohort design ISRCTN15106246. Patients: 465 COPD patients (to detect a difference 
between groups of 25%, 80% statistical power, 95% confidence level, 40% expected 
losses), with inhaled treatment, written consent. Non-probabilistic consecutive sam-
pling. Allocation: Patients without strong preferences for a treatment are randomised: 
RCT group (block randomization), and those with strong preferences are given their 
choice: PPS group. Variables: Primary outcomes: Performance of correct inhalation tech-
nique. Secondary outcomes: Pick flow, dyspnea (Baseline dyspnea index), Functional 
status (forced spirometry). Interventions: Intervention-A: Written information. A leaf-
let with the correct inhalation technique for the main inhaler devices used in our 
area. Intervention-B: Intervention-A + individual training (by instructors). Follow-up: 3 
month, visits: baseline, 1 month, 3 month. Statiscal analysis: Mean, frequency, 95% 
confidence interval at baseline. Number Needed to Treat for a benefit (NNT) was cal-
culated. Intention to treat analysis. Results: Predominance of males (91.4%), mean 
age 69.8 years (CI95%, 69.00-70.59); FEV1(mean)= 55.91% (IC95%, 53.62-58.2), mixed 
respiratory pattern (65.9%). Severity stage: 15.7% mild, 44.1% Moderate, 40.3% Severe. 
Pharmacological treatment: inhaled-beta2-adrenergic (88.8%); inhaled-corticosteroids 
(76.7%); inhaled-anticholinergic (70.7%); mucolitycs (19.4%); xanthine (7.3%); oral-corti-
costeroids (1.3%). BDI: grade 2. Primary outcome: better inhalation technique (p= 0.002) 
in the PPS group, NNT= 7.4 (IC95%, 4.52-20).Among the RCT cohorts: there was no differ-
ence between control and intervention A and there were statistically significative dif-
ferences between intervention B versus control (p< 0.0001), NNT= 2.44 (IC95%, 1.87-3.5) 
and versus intervention A, NNT= 2.85 (IC95%, 2.08-4.56). In the PPS cohorts: there was a 
difference (p< 0.0001) between intervention B versus intervention A, NNT= 2.33 (IC95%, 
1.5-3.2). cOnclusiOns: The performance of a correct inhalation Technique improves 
with monitor training. The patients’ preferences enhance the efficacy of intervention.
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Respiratory symptoms are common among adults living in Russian cities, which may 
indicate high COPD incidence. Awareness of COPD in Russia is lacking. A high propor-
tion of adults aged 40 and older in Russia report frequent respiratory symptoms, and 
these symptoms are associated with significantly worse health status.
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thE RElationShiP bEtwEEn coPD aSSESSmEnt tESt (cat) anD Eq-5D in a 
REal woRlD PatiEnt PoPUlation
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Objectives: COPD is a chronic lung disease that has a detrimental effect upon 
patient’s quality of life. The COPD Assessment Tool (CAT) has been developed 
to measure the impact of the disease. This research explores the relationship 
between the disease-specific CAT, and the general health related utility measure 
EQ-5D. MethOds: COPD is a chronic lung disease that has a detrimental effect 
upon patient’s quality of life. The COPD Assessment Tool (CAT) has been developed 
to measure the impact of the disease. This research explores the relationship 
between the disease-specific CAT, and the general health related utility meas-
ure EQ-5D. Results: A scatter plot relating CAT score to EQ-5D showed that the 
relationship is non-linear. Variance of the EQ-5D score increased with CAT score, 
suggesting the increasing influence of confounding factors for patients report-
ing a higher CAT score (CAT score range variance: 0-10: 0.013, 11-20: 0.026, 21-30: 
0.050 and 31-40: 0.126). A generalized linear model was used to account for the 
non-linear relationship, and control for confounding influences of age, gender, 
physician-perceived COPD severity and number of concomitant conditions, with 
no assumption of constant variance. The relationship between CAT and reversed 
EQ-5D was positive and significant (coefficient 0.070, p-value < 0.0001), illustrating 
higher CAT score was associated with lower EQ-5D. A one point increase in CAT 
score resulted in an approximate 7.2% relative decrease in EQ-5D score. Similarly, 
significant (p-value < 0.0001) negative relationships observed for older patients 
(coefficient 0.016), female gender (coefficient 0.147), greater severity (coefficient 
0.469), and a higher number of comorbidities (coefficient 0.070). cOnclusiOns: 
Increasing COPD impact as measured by the CAT was associated with lower EQ-5D 
scores. However, the increasing variance of EQ-5D for patients with higher CAT 
scores demonstrates the need for both COPD impact and overall health status 
assessment.
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Objectives: Previous research has indicated a strong relationship between 
asthma symptoms and asthma-specific quality of life (QoL). However, past meas-
ures of asthma-specific QoL typically confound symptoms and functional impair-
ment with QoL, which in turn may cause a misleadingly high inter-correlation. 
The current research uses a newly developed measure of asthma-specific QoL 
(the RAND-Impact of Asthma on Quality of Life; RAND-IAQL) that controls for 
asthma symptoms and functional impairment while assessing the degree of 
asthma impact or burden. Using this new measure, we model the relationship 
between asthma specific quality of life, generic quality of life, asthma control, 
and comorbid conditions commonly associated with asthma. MethOds: Using 
a diverse sample of adults with asthma (N= 2032), we use structural equation 
models (SEM) to establish the relationships and suppression effects of asthma 
control, symptoms, comorbidities (e.g., COPD, Sinusitis), and multiple PROMIS QoL 
instruments (including anxiety and social QoL) on the prediction of asthma-
specific QoL. SEM models will be presented sequentially in order to evaluate the 
relative utility of increasingly complex models using likelihood ratio tests and 
changes in the amount of IAQL variance that is accounted for by each added 
predictor (latent) variable. Results: Close fitting SEM models suggest that 
“interference” caused by asthma, an indicator commonly used to measure asthma 
control, is most strongly related to asthma-specific QoL. Contrary to the research 
literature, symptoms of asthma (including shortness of breath, wheezing, and 
cough) and comorbid diseases are less strongly related to asthma specific QoL 
than are general assessments of interference and generic measures of anxiety 
and limitations in social functioning. cOnclusiOns: Asthma-specific QoL is best 
understood as the degree to which asthma impacts or burdens ones daily life. 
While asthma symptoms, control, and general QoL are highly inter-correlated, 
asthma control (primarily interference) is differentially predictive of asthma-
specific QoL.
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Objectives: In response to recommendations from the 2010 NHLBI Asthma 
Outcomes Workshop, we developed a new system for measuring the impact of 
asthma on quality of life (QoL) that avoids confounding QoL with asthma symp-
tomatology and functional impairment. This presentation summarizes the process 
of developing and validating an item bank and short-forms that measure patients’ 
perceptions of the impact or bother of asthma on their life. MethOds: Focus 
groups, supplemented by literature review and expert panel recommendations 
were used to identify key QoL dimensions and develop a pool of items which were 
refined based on cognitive interviews. Items were field-tested using a diverse 
national sample of adults with asthma (N= 2032). Modern measurement theory 
was used to develop an item bank and short forms. We validated our short-forms 
against the Marks AQLQ; ACT; and generic QoL measures. Discriminant validity 
was examined by evaluating scores from respondents who differed according 
one study. cOnclusiOns: Our review showed that PROs are often included in COPD 
product labels in Europe and in the USA. Although the FDA and the EMA agree on a 
general level, the FDA seems more restrictive in the label wording.
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Fernández-Lahera J., Gonzalez A., Prados C., F-Bujarrabal J., Martínez A.
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Objectives: To assess the relationship between the questionary of quality of life 
“COPD assessment test” (CAT) and clinical, functional and comorbidity parameters 
and compare patient perceptions of symptoms with that of their family mem-
bers. MethOds: We analysed demographic (age, sex, BMI), lung function (FEV1%) 
and comorbidity variables (Charlson index) in patients with stable COPD. Patients 
and family members independently completed the CAT (family members reported 
their observations of the patient). Results: We included 70 patients (83% men, 
mean age 72±9.4 years, BMI 27.8±4.2 kg/m2, Charlson index (ChI) 2.41±1.7, mean 
FEV1% 57.1±15.1%. Air flow limitation (GOLD): 7 patients (9%) mild, 36 (53%) moder-
ate, 24 (34%) severe and 3 (4%) very severe. There was a significant negative cor-
relation between CAT and FEV1% (r= -0.265, p< 0.0028) but no correlation between 
CAT and ChI, age or BMI. A comparison of CAT scores between the patients and 
their family members showed that 61% of the patients underestimated and 33% 
overestimated their symptoms (CAT scores: 15.5±7.9 (patient) vs. 17.1±7.7 (family) 
(p< 0.038); correlation: (r= 0.72; p< 0.001). We observed correlations in the 8 CAT items. 
We found significant differences between the patients and their family members 
in items 1: coughing (p< 0.015), 3: chest tightness (p< 0.005) and 6: confidence leav-
ing home (p< 0,015) and in overall score (p< 0.038). cOnclusiOns: 1. We found 
a negative correlation between the CAT and FEV1but not between the CAT and 
Charlson index. 2. Patients underestimate their symptoms. Cough, chest tightness 
and confidence leaving home are the issues items that had the greatest discrepancy 
between patients and family members.
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takinG lEUkotRiEnE moDifiERS vERUS thoSE takinG inhalED 
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Objectives: To assess treatment satisfaction between patients with self-reported 
asthma for two classes of asthma treatments, leukotriene modifiers (LM group) 
and inhaled corticosteroids (IC group), using a novel patient community in the 
U.S. MethOds: Participants were identified via MediGuard, a digital patient plat-
form where patients enroll online to be part of a digital patient community. All 
information was obtained through participant self-report. Patients were invited 
to complete the Treatment Satisfaction Questionnaire for Medication (TSQM), a 
patient reported outcome (PRO) instrument, at random time points between 2009 
and 2011. Domain scores of the TSQM were compared between the IC and LM 
groups using regression analyses, adjusting for age, gender, self-reported severity 
and number of co-medications. Results: A total of 736 patients were included 
for the IC group, and 647 for LM group. Average ages were comparable (56.3 years 
(SD= 13.8) for IC; 54.9 (13.5) for LM). Both groups were predominantly female (76.3% 
IC; 83.2%, LM). Effectiveness domain scores were similar between IC and LM groups 
(p= 0.502). LM users reported significantly higher scores (i.e., increased satisfaction) 
for other domains: side effects (97.1 (SD= 0.8) vs. 93.5 (0.7), resp.); convenience (89.2 
(0.8) vs. 81.6 (0.7), resp.); global satisfaction (72.3 (1.1) vs. 67.3 (1.0). cOnclusiOns: 
Patients in the LM group reported higher satisfaction in the convenience and global 
satisfaction domains than the IC group. Patients in the LM group reported less 
interference with side effects than the IC group. Providing patients with informa-
tion on population-based satisfaction scores for these two medications could help 
inform patients’ treatment selection decisions.
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SymPtomS of coPD in URban RUSSia amonG aDUltS 40 yEaRS anD olDER
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Objectives: Chronic obstructive pulmonary disease (COPD) is a major cause of dis-
ability worldwide, but awareness of COPD and information regarding the burden of 
this disease are lacking worldwide, including Russia. The aim of the current study 
was to assess the prevalence of COPD symptoms (cough with mucous, wheezing, and 
shortness of breath) among a representative sample of adults aged 40 and above in 
major cities in Russia. MethOds: Data was obtained from the 2011 Russia National 
Health and Wellness Survey, a cross-sectional survey of the adult population in the 
city adult population in Russia which includes information on awareness, experi-
ence, and diagnosis of medical conditions, health care-related attitudes, demographic 
characteristics, and health outcomes. The frequency of COPD symptoms was assessed 
using the Lung Function Questionnaire, and health status was assessed using the 
SF-12v2. Those experiencing a symptom at least ‘sometimes’ were compared to 
those who experienced the symptom ‘rarely’ or less using independent-samples 
t-tests. Results: A total of 5920 adults aged 40 and older completed the survey. After 
weighting, 45%, 27%, and 18% reported shortness of breath, coughing up mucous, and 
wheezing, respectively, and 54% reported at least one symptom. Only 23% of those 
surveyed were aware of COPD; awareness of COPD was greatest among those with the 
most symptoms but even among those with all three symptoms, only 31% were aware 
of the condition. Experience of each symptom was associated with worse mental 
and physical component summary scores on the SF-12v2, with decrements ranging 
from 2-6 points depending on the symptom and score considered. cOnclusiOns: 
